Author: Jesse Landry

There’s something ironic about calling it “decentralized finance” when most people still need a PhD, a YouTube tutorial, and a prayer just to earn yield on their crypto. But YieldClub isn’t playing that game, they’re rewriting it, one tap at a time. Founded in 2025 and now stepping out of stealth with a $2.5M pre-seed round, YieldClub is dead set on making high-yield crypto savings a mainstream affair, without the mental gymnastics. Think 12% APY on stablecoins, no custodial surrender, and no friction, just clean, consumer-grade simplicity on top of audited DeFi protocols like Morpho. (That’s $2.4B on Ethereum and…

It’s not every day you watch a startup walk into a room full of private equity sharks, drop 26 million verified company records on the table, and say, “We built a better operating system, try to keep up.” Meridian just closed $7M in Seed funding, led by the sharp minds at 645 Ventures. Chaac Ventures returned as an existing backer, and the rest of the cap table reads like a who’s who of private equity, credit, and M&A law, because, in a twist that shouldn’t surprise anyone paying attention, the early adopters of this platform didn’t just use it, they…

In crypto, everyone wants to decentralize the future, until it’s time to send payroll, reconcile the treasury, or explain to the CFO why $600K just got stuck bridging to Arbitrum. The Web3 dream has always sounded slick on a slide deck, but running ops across seven chains with six wallets and a cold storage key that lives in Chad’s sock drawer? That’s not a system, that’s a liability disguised as innovation. Stackup isn’t here to sell you a vibe, they’re here to fix what’s broken. Stackup just raised $4.2M in seed funding to rewire how crypto businesses manage their money,…

The genome doesn’t lie, it whispers secrets most diagnostics can’t hear. But Arima Genomics, Inc. doesn’t just listen. It decodes the full spatial symphony. And this week, the biotech world caught that signal loud and clear. On June 17, 2025, Arima Genomics dropped two back-to-back moves that would make any chess grandmaster sweat. First, they named genomics OG Tom Willis, PhD as Chief Executive Officer. This isn’t your average suit with a nice resume. We’re talking about the guy who co-founded Sequenta (remember ClonoSEQ? Yeah, that one, NCCN-endorsed, still hitting clinical charts) and built arAllele BioScience before most of biotech…

When you’re building production AI systems and the pipes keep leaking, it’s not your LLM’s fault, it’s the infrastructure you laid it on. The whole stack is buckling under the weight of yesterday’s paradigms, retrofitted Spark jobs, and duct-taped pipelines no one wants to own. That’s the problem Typedef was built to solve, by skipping the legacy trauma and going straight to the source. Typedef just stepped out of stealth with a $5.5M seed round, led by Pear VC with Verissimo Ventures, Monochrome Ventures, Tokyo Black, and angels like Wes McKinney and Chris Riccomini backing the vision. And the vision…

When the future of ophthalmology starts reading like a data scientist’s fever dream and a clinical trial coordinator’s fantasy checklist, you know something real just happened. Amaros Inc., the stealth-smart, Silicon Valley startup whispering to the soul of ophthalmic care, just closed its Series A round. The amount? Undisclosed. The implications? Loud enough to echo through every retinal practice and pharma boardroom from Atherton to Basel. Founded in 2019 by Vartan Ghazarossian, Ph.D. and Ben Toker, two names that carry weight in both lab coats and startup circles, Amaros is doing something most health tech companies claim but rarely deliver:…

Snack bars used to be that thing you grabbed when you were either too busy to eat real food or trying to convince yourself that honey-glazed cardboard counted as “health.” Then All In Food stepped in and reminded the market what it looks like when mission, quality, and retail firepower all show up at the same time, and actually taste good. Born from the raw reality of a humanitarian trip to Liberia in 2008, the brand formerly known as This Bar Saves Lives wasn’t dreamed up in a WeWork conference room with a whiteboard full of hype. It was sparked…

They say healthcare moves slow. Commure Inc. just dropped a brick of truth on that myth, $200 million in growth financing, led by General Catalyst’s Customer Value Fund. That’s not just fuel. That’s a spotlight, a signal, a siren wailing down the streets of San Francisco saying, “The future showed up early, get in or get run over.” This isn’t some equity-for-air deal. This is performance-tied, non-dilutive capital. Translation? Commure’s product already delivers. Hemant Taneja, who co-founded Commure and also runs the ship at General Catalyst, saw it early and bet heavy. Now the company’s valuation sits at $6 billion,…

What happens when a seasoned biotech founder with a billion-dollar exit under his belt steps back into the arena with a product the FDA already calls “breakthrough”? You get Paradigm Therapeutics, a name that doesn’t just suggest a shift, it promises one. Founded in 2023 by Dr. Robert Ryan, the same Robert Ryan who built Scioderm and sold it to Amicus Therapeutics for a cool $957M, Paradigm Therapeutics isn’t here to pitch another miracle cream, it’s here to deliver one. Based out of Mount Pleasant, South Carolina (because not every revolution needs a Silicon Valley zip code), the company is…

Some startups play in the energy space. NovaSpark breathes it in, literally. Hydrogen. Pulled from thin air. Packaged into a mobile, trailer-mounted system that generates clean fuel and electricity, on-demand. No external water sources, no fuel convoys, no infrastructure. Just atmospheric alchemy engineered for the edge of the map. Born from a U.S. military initiative to fuel operations in isolated, high-risk environments, NovaSpark Energy Corporation isn’t tinkering with tomorrow’s power, they’re deploying it. Straight out of Houston with Louisiana grit and Washington DC reach, this crew builds tech that can fuel a drone, power a field hospital, or keep the…